Please login to the form below

Not currently logged in
Email:
Password:

ado-trastuzumab emtansine

This page shows the latest ado-trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,

Latest news

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or

  • NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations

    The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that

  • A new decade of disruption: meeting the biosimilar challgenge A new decade of disruption: meeting the biosimilar challgenge

    High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction

  • Roche says Tecentriq Roche says Tecentriq "off to a good start"

    Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.

  • NHS patients set to be denied Opdivo and Kadcyla NHS patients set to be denied Opdivo and Kadcyla

    Kadycla discounts insufficient. Meanwhile, NICE's final rejection of Kadcyla (ado-trastuzumab emtansine) comes despite Roche offering undisclosed discounts on the drug's £90, 000-a-year list price, and after

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics